Third Harmonic Bio, Inc. (THRD)
NASDAQ: THRD · Real-Time Price · USD
10.84
-0.04 (-0.37%)
Dec 20, 2024, 4:00 PM EST - Market closed

Company Description

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases.

The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.

It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions.

The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019.

Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.

Third Harmonic Bio, Inc.
Third Harmonic Bio logo
Country United States
Founded 2019
IPO Date Sep 15, 2022
Industry Biotechnology
Sector Healthcare
Employees 30
CEO Natalie Holles

Contact Details

Address:
1700 Montgomery Street, Suite 210
San Francisco, California 94111
United States
Phone 209 727 2457
Website thirdharmonicbio.com

Stock Details

Ticker Symbol THRD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001923840
CUSIP Number 88427A107
ISIN Number US88427A1079
Employer ID 83-4553503
SIC Code 2834

Key Executives

Name Position
Natalie C. Holles Chief Executive Officer and Director
Julie Person Chief Administrative Officer
Dr. Edward R. Conner M.D. Chief Medical Officer
Christopher Murphy Chief Financial and Business Officer
Jennifer Dittman Chief Operating Officer
Dr. Christopher J. Dinsmore Ph.D. Chief Scientific Officer
Steven P. Sweeney Senior Vice President of Development Operations
Dennis Dean Ph.D. Chief Non-Clinical Development Officer
Ommer Chohan Treasurer and Secretary

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024 8-K Current Report
Nov 7, 2024 10-Q Quarterly Report
Nov 5, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Oct 28, 2024 144 Filing
Sep 27, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Sep 19, 2024 144 Filing